What does Strybol Pharma Groep do?

Strybol Pharma Groep is a pharmacy in Brugge. Private Limited, started on 16 December 2011, 6 establishments.

What is the address of Strybol Pharma Groep?

The registered office of Strybol Pharma Groep is located at Maalse Steenweg 319, 8310 Brugge.

Is Strybol Pharma Groep still active?

Yes. According to the CBE (30 October 2026) Strybol Pharma Groep is active, legal situation “Normale toestand”, started on 16 December 2011.

Is Strybol Pharma Groep registered on Peppol?

Yes, Strybol Pharma Groep is registered on the Peppol network with ID 0208:0841947033.

What is the enterprise number of Strybol Pharma Groep?

The enterprise number of Strybol Pharma Groep is BE0841947033.

When was Strybol Pharma Groep founded?

Strybol Pharma Groep was founded on 16 December 2011.

Who are the directors of Strybol Pharma Groep?

According to the 2025 annual accounts, the directors of Strybol Pharma Groep are: STRYBOL WOUT PHARMA BV, STRYBOL IBEN PHARMA BV, STRYBOL INVEST BV.

Is Strybol Pharma Groep a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 December 2011; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account; 6 establishments in the CBE.

How much profit did Strybol Pharma Groep make in 2025?

Strybol Pharma Groep posted a profit after taxes of € 282,396 in financial year 2025.

What is the revenue of Strybol Pharma Groep?

As a small company, Strybol Pharma Groep is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,466,805.

How much does an employee at Strybol Pharma Groep earn?

The average wage cost per full-time employee at Strybol Pharma Groep was € 75,400 in 2025: staff costs of € 927,465 for 12.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Strybol Pharma Groep have?

According to the 2025 annual accounts, Strybol Pharma Groep has 12.3 full-time equivalents (FTE).

Strybol Pharma Groep (Private Limited) - Brugge

Dossier Strybol Pharma Groep, printed on 30 October 2026 from databakkes.be/en/0841947033/strybol-pharma-groep. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Strybol Pharma Groep from Brugge, company number BE0841947033, closed financial year 2025 with a result of € 282,396 after tax. For that financial year Strybol Pharma Groep recorded a gross margin of € 1.5 million and equity of € 391,741. Compared with financial year 2024, the result moved from € 65,575 to € 282,396. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.

What it is worth Growing

€ 391,741

▲ 258% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 282,396

▲ € 216,821 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 102,259

▲ 273% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 373,141.

People and assets in 2025

Full-time equivalents

12.3

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 927,465

€ 75,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 15,530

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 10 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 2.2 million

€ 234,102 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.

Owed to suppliers

€ 424,444

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 164,949

▲ € 164,921 vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 71,184 Gross margin 2022: € 71,184 First fiscal year in the series	€ 159,926 Gross margin 2023: € 159,926 ▲ 125% vs 2022 (€ 71,184) Favourable step	€ 68,658 Gross margin 2024: € 68,658 ▼ 57% vs 2023 (€ 159,926) Unfavourable step	€ 1,466,805 Gross margin 2025: € 1,466,805 ▲ € 1.4 million vs 2024 (€ 68,658) Favourable step	▲ € 1.4 million
Profit after taxes	€ 59,519 Profit after taxes 2022: € 59,519 First fiscal year in the series	€ 160,333 Profit after taxes 2023: € 160,333 ▲ 169% vs 2022 (€ 59,519) Favourable step	€ 65,575 Profit after taxes 2024: € 65,575 ▼ 59% vs 2023 (€ 160,333) Unfavourable step	€ 282,396 Profit after taxes 2025: € 282,396 ▲ € 216,821 vs 2024 (€ 65,575) Favourable step	▲ € 216,821
Equity	€ 18,936 Equity 2022: € 18,936 First fiscal year in the series	€ 109,270 Equity 2023: € 109,270 ▲ € 90,333 vs 2022 (€ 18,936) Favourable step	€ 109,345 Equity 2024: € 109,345 Unchanged (€ 109,270) Favourable step	€ 391,741 Equity 2025: € 391,741 ▲ 258% vs 2024 (€ 109,345) Favourable step	▲ 258%
Total debts	€ 29,692 Total debts 2022: € 29,692 First fiscal year in the series	€ 70,236 Total debts 2023: € 70,236 ▲ 137% vs 2022 (€ 29,692) Unfavourable step	€ 65,654 Total debts 2024: € 65,654 ▼ 7% vs 2023 (€ 70,236) Favourable step	€ 2,904,735 Total debts 2025: € 2,904,735 ▲ € 2.8 million vs 2024 (€ 65,654) Unfavourable step	▲ € 2.8 million
Cash	€ 4,915 Cash 2022: € 4,915 First fiscal year in the series	€ 6,196 Cash 2023: € 6,196 ▲ 26% vs 2022 (€ 4,915) Favourable step	€ 27,432 Cash 2024: € 27,432 ▲ € 21,237 vs 2023 (€ 6,196) Favourable step	€ 102,259 Cash 2025: € 102,259 ▲ 273% vs 2024 (€ 27,432) Favourable step	▲ 273%
Retained profit	€ 336 Retained profit 2022: € 336 First fiscal year in the series	€ 90,670 Retained profit 2023: € 90,670 ▲ € 90,333 vs 2022 (€ 336) Favourable step	€ 90,745 Retained profit 2024: € 90,745 Unchanged (€ 90,670) Favourable step	€ 373,141 Retained profit 2025: € 373,141 ▲ € 282,396 vs 2024 (€ 90,745) Favourable step	▲ € 282,396
Dividend	€ 26,500 Dividend 2022: € 26,500 First fiscal year in the series	€ 70,000 Dividend 2023: € 70,000 ▲ 164% vs 2022 (€ 26,500) Unchanged	€ 65,500 Dividend 2024: € 65,500 ▼ 6% vs 2023 (€ 70,000) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 65,500) Unchanged	▼ 100%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 2,231,692 Bank debt 2025: € 2,231,692 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 48,628 Balance sheet total 2022: € 48,628 First fiscal year in the series	€ 179,506 Balance sheet total 2023: € 179,506 ▲ 269% vs 2022 (€ 48,628) Unchanged	€ 174,999 Balance sheet total 2024: € 174,999 ▼ 3% vs 2023 (€ 179,506) Unchanged	€ 3,296,475 Balance sheet total 2025: € 3,296,475 ▲ € 3.1 million vs 2024 (€ 174,999) Unchanged	▲ € 3.1 million
Employees (FTE)	-	0 Employees (FTE) 2023: 0 First fiscal year in the series	0 Employees (FTE) 2024: 0 Unchanged (0) Unchanged	12.3 Employees (FTE) 2025: 12.3 Unchanged (0) Unchanged

Key figures of Strybol Pharma Groep, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Strybol Pharma Groep?

What happened at Strybol Pharma Groep in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 2, 2026 New annual accounts for financial year 2025: profit of € 282,396 (▲ € 216,821 vs 2024). Source: NBB ↗
Jan 1, 2026 New establishment in Brugge. KBO
Jan 21, 2025 New establishment in Brugge. KBO
Jan 1, 2025 New establishment in Maldegem. KBO
Jan 1, 2025 New establishment in Maldegem. KBO
Jan 1, 2025 New establishment in Brugge. KBO
2024 STRYBOL WOUT PHARMA BV became a director. NBB
2024 STRYBOL IBEN PHARMA BV became a director. NBB

In short

From € 59,519 profit in 2022 to € 282,396 profit in 2025.

Paid € 146,775 in corporate taxes since 2022.

Best year ever: 2025, with € 282,396 profit.

On average € 119,300 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Strybol Wout Pharma 45%

Strybol Iben Pharma 45%

The stake of Strybol Wout Pharma, Strybol Iben Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Strybol Pharma Groep

Behind Strybol Pharma Groep are STRYBOL WOUT PHARMA BV, STRYBOL IBEN PHARMA BV and STRYBOL INVEST BV. The shares are held by Strybol Wout Pharma (45%) and Strybol Iben Pharma (45%).

Directors

According to the 2025 annual accounts

STRYBOL WOUT PHARMA BV

Director · represented by Strybol Wout

Also active at: STRYBOL DE ZEVEN TORENTJES, APOTHEEK SMEKENS, Strybol Invest, PHARMA 310505, Strybol De Berken, Strybol Sint-Gillis

since 2024

STRYBOL IBEN PHARMA BV

Director · represented by Strybol Iben

Also active at: STRYBOL DE ZEVEN TORENTJES, APOTHEEK SMEKENS, Strybol Invest, PHARMA 310505, Strybol De Berken, Strybol Sint-Gillis

since 2024

STRYBOL INVEST BV

Director · represented by Strybol Geert

Also active at: De Rotonde Apotheek, APOTHEEK DEBAENST, APOTHEEK SMEKENS, De Berken Apotheek, SINT-GILLIS APOTHEEK

since 2012

Shareholders

Strybol Wout Pharma

45%

Strybol Iben Pharma

45%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Maalse Steenweg 319

8310 Brugge

2.370.360.690

Kleitkalseide 89

9990 Maldegem

Active since 1 January 2025

2.370.360.789

Brugse Steenweg 174

9990 Maldegem

Active since 1 January 2025

2.370.360.888

Odegemstraat 29

8310 Brugge

Active since 1 January 2025

2.370.360.987

Annuntiatenstraat 56

8000 Brugge

Active since 21 January 2025

2.384.857.737

Baron Ruzettelaan 175

8310 Brugge

Active since 1 January 2026

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0841.947.033
VAT number: BE 0841.947.033
Registered office: Maalse Steenweg 319, 8310 Brugge
Names & denominations: Strybol Pharma Groep
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 16 December 2011
Peppol: Active · Active since 30 Jan 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

Strybol Pharma Groep

Financials

What happened to Strybol Pharma Groep?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions